"Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion. In addition to potential future payments tied to specific clinical and regulatory milestones, Pfizer said it will acquire all outstanding shares of Metsera stock for $47.50 per share."
"Metsera shares closed at $33.32 on Friday and surged more than 60% on Monday to as high as $54.47 per share. New York-based Metsera emerged from stealth mode last year to take on the weight-loss market and completed its initial public offering earlier this year. The acquisition, which has been unanimously approved by the boards of directors at both companies, will help Pfizer gain a foothold in the increasingly competitive market for weight-loss drugs."
Pfizer will acquire all outstanding shares of Metsera for $47.50 per share, with the deal valued up to $7.3 billion including potential milestone payments. Metsera brings a portfolio of four medications targeting obesity and cardiometabolic diseases and completed an initial public offering earlier this year after emerging from stealth mode. Metsera shares jumped over 60% on the acquisition announcement. The transaction received unanimous board approval at both companies. Metsera's pipeline is projected to deliver more than $5 billion in combined peak sales, with likely drug launches expected around 2028–2029, enhancing Pfizer's growth prospects amid rising competition in weight-loss therapies.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]